Latest news with #APJ
Yahoo
an hour ago
- Health
- Yahoo
BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions
Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits observed in combination with incretin therapy Data support development of next-generation APJ agonists for obesity and key comorbidities EMERYVILLE, Calif., June 21, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ('BioAge', 'the Company'), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that it will present new preclinical data supporting apelin receptor (APJ) agonism for the treatment of diabetic obesity and heart failure with preserved ejection fraction (HFpEF). The data will be presented at the American Diabetes Association's 85th Scientific Sessions, held June 20–23, 2025, in Chicago, Illinois. 'Our preclinical data demonstrated that APJ activation can confer multiple benefits in models of diabetic obesity and heart failure, and enhance the effects of incretin therapy,' said Kristen Fortney, PhD, CEO and co‑founder of BioAge. 'We are advancing next‑generation APJ agonists to translate this promising biology into new therapies for obesity and its major comorbidities.' APJ is the receptor for apelin, an exercise-induced signaling molecule known as an exerkine. Apelin has been shown in preclinical studies to have the potential to recapitulate many of the downstream benefits of exercise. BioAge's discovery platform identified apelin signaling as a therapeutic target based on analysis of human aging cohorts, which revealed that higher levels of circulating apelin are predictive of improved physical function and increased longevity. BioAge has shown that in preclinical obesity models, APJ agonism can approximately double the weight loss induced by GLP-1 receptor agonists while restoring body composition and muscle function, suggesting that APJ agonists could serve as pharmacological exercise mimetics to enhance incretin therapy. BioAge is advancing multiple APJ agonist approaches, including both oral small-molecule and long-acting injectable formulations, with an IND filing targeted for 2026 [link]. In their two presentations, BioAge CMO and EVP Research Paul Rubin, MD, and scientist Shijun Yan, PhD, MBA, will present data that demonstrated that in preclinical models of diabetic obesity and HFpEF, APJ agonist treatment had potential as monotherapy that could be enhanced in combination with incretin therapies. —Dr. Rubin's oral presentation will show that in mouse models of diabetic obesity, APJ agonist monotherapy reduced HbA1c to levels comparable to lean controls and improved glucose tolerance by 25%. When combined with an incretin, APJ agonism further improved glycemic control compared to the incretin alone. Currently, fewer than half of patients with type 2 diabetes achieve optimal glycemic control on current incretin therapies. — Dr. Yan's poster will show that in a mouse model of obesity-associated heart failure, APJ agonist monotherapy reduced cardiac hypertrophy and suppressed markers of cardiac injury. Combination of APJ agonism with an incretin provided enhanced cardioprotective benefits and greater weight loss compared to either treatment alone. Over half of heart failure patients have preserved ejection fraction, and approximately two-thirds of these patients have obesity. Current therapeutic options for obesity-associated HFpEF remain limited. Oral presentation: Saturday Jun 21, 2025 5:00 PM - 5:15 PM CDTTitle: An Oral Apelin Receptor Agonist Enhances Glycemic Control in Preclinical Models of Diabetic Obesity Both as Monotherapy and in Combination with TirzepatideSession: Early Phase, Post Hoc, and Subgroup Analyses from Clinical Trials Testing Incretin-Based Therapies—Take 1; W181 A-CPresenter: Paul Rubin, MD, Chief Medical Officer and EVP-Research Poster presentation: Sunday Jun 22, 2025 12:30 PM - 1:30 PM CDTTitle: The Apelin Receptor Agonist Azelaprag Shows Cardioprotective Effects as Monotherapy and Enhanced Benefits with Semaglutide in a Diet-Induced Obesity Model of Heart Failure with Preserved Ejection FractionSession: Poster Hall F1, Board No. 866Presenter: Shijun Yan, PhD, MBA, Senior Scientist, In Vivo Biology The visual materials for the presentations will be made available on the BioAge investor website concurrent with the beginning of their respective sessions. About BioAge Labs, Inc. BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The Company's lead product candidate, BGE-102, is a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for obesity. BGE-102 has demonstrated significant weight loss in preclinical models both as monotherapy and in combination with GLP-1 receptor agonists. IND submission and initiation of a Phase 1 SAD/MAD trial are planned for mid-2025, with initial SAD data anticipated by end of year. The Company is also developing long-acting injectable and oral small molecule APJ agonists for obesity. BioAge's additional preclinical programs, which leverage insights from the Company's proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging. Forward-looking statements This press release contains 'forward-looking statements' within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our plans to develop and commercialize our product candidates, including BGE-102 and our APJ program, the timing and results of our planned clinical trials, risks associated with clinical trials, including our ability to adequately manage clinical activities, the timing of our IND filing for BGE-102 or our APJ program, our ability to obtain and maintain regulatory approvals, the clinical utility of our product candidates or their ultimate ability to treat human disease, the expected timeline for completing proteomic analysis, anticipated analytical results and the potential for identifying novel therapeutic targets, and general economic, industry and market conditions. These forward-looking statements may be accompanied by such words as 'aim,' 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'possible,' 'will,' 'would,' and other words and terms of similar meaning. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: our ability to develop, obtain regulatory approval for and commercialize our product candidates; the timing and results of preclinical studies and clinical trials; the risk that positive results in a preclinical study or clinical trial may not be replicated in subsequent trials or success in early stage clinical trials may not be predictive of results in later stage clinical trials; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events; failure to protect and enforce our intellectual property, and other proprietary rights; failure to successfully execute or realize the anticipated benefits of our strategic and growth initiatives; risks relating to technology failures or breaches; our dependence on collaborators and other third parties for the development of product candidates and other aspects of our business, which are outside of our full control; risks associated with current and potential delays, work stoppages, or supply chain disruptions, including due to the imposition of tariffs and other trade barriers; risks associated with current and potential future healthcare reforms; risks relating to attracting and retaining key personnel; changes in or failure to comply with legal and regulatory requirements, including shifting priorities within the U.S. Food and Drug Administration; risks relating to access to capital and credit markets; and the other risks and uncertainties that are detailed under the heading 'Risk Factors' included in BioAge's Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) on May 6, 2025, and BioAge's other filings with the SEC filed from time to time. BioAge undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or Chris Patil, media@ IR: Dov Goldstein, ir@ Partnering: partnering@ Web:
News18
10 hours ago
- Entertainment
- News18
Revealed! Salman Khan's Iconic 'Tere Naam' Hairstyle Was Inspired By THIS Person
Last Updated: Salman Khan revealed on The Great Indian Kapil Show 3 that his Tere Naam hairstyle was inspired by a great political leader. Tere Naam was his career's turning point. Salman Khan is the first guest of the new season of The Great Indian Kapil Show 3 on Netflix. The first episode of the new season dropped on June 21, featuring Salman laughing his heart out while also making fans chuckle with his witty one-liners. However, the superstar also shared several tidbits about his films that are bound to leave you surprised. One of the highlights was Bollywood's Bhaijaan revealing the real inspiration behind his hairstyle in Tere Naam. Salman Khan as the college hunk Radhe Mohan sported a mid-parted hairstyle, denim jackets, and his signature bracelet in Tere Naam. His look inspired hundreds of fans, many of whom also tried to pull off the same style. In fact, Salman's hair in the film continues to be discussed even today. The actor, at the The Great Indian Kapil Show 3, revealed that his hairstyle was inspired by former President APJ Abdul Kalam and yesteryear actor Rahul Roy. On the first episode of The Great Indian Kapil Show, Salman Khan shared, 'Ye jo Tere Naam ka jo look hai, woh actually inspired tha Abdul Kalam saab se aur uss dauran I think Rahul Roy ka bhi same hairstyle tha. I thought ki jo small town hero hota hai na, unke humesha lambe baal hotey hai. The yesteryear heroes all had long hair, toh waha se ye aaya tha. (My hair in Tere Naam is inspired by Abdul Kalam sir, even Rahul Roy had the same hairstyle. I thought a small town hero would have long hair like this. The yesteryear heroes all had long hair, which inspired me)." All you need to know about Salman Khan's Tere Naam Released in 2003, Tere Naam is one of Salman Khan's most iconic and emotionally intense films. The film is the Hindi remake of filmmaker Bala's 1999 Vikram-starrer superhit film, Sethu. Directed by Satish Kaushik, it features Salman as Radhe, a troubled young man whose love story takes a tragic turn. His powerful performance, raw intensity, and memorable mid-parted hairstyle left a lasting impression on audiences. The film's music, composed by Himesh Reshammiya, also became a massive hit. Tere Naam marked a turning point in Salman's career, showcasing his range as an actor beyond action and comedy. The film starred him alongside Bhumika Chawla. First Published:
Hindustan Times
11 hours ago
- Entertainment
- Hindustan Times
Salman Khan reveals this former Indian President inspired his look in Tere Naam
Actor Salman Khan's haircuts and outfits have been quite the inspiration for his fans through the years. But one look that seems most memorable has to be his long hair parted down the middle in the 2003 film Tere Naam. On The Great Indian Kapil Sharma Show season 3 on Netflix, Salman revealed that this former Indian President was the inspiration for the look. (Also Read: Salman Khan's bodyguard pushes away Aamir Khan's son Junaid Khan at Sitaare Zameen Par premiere. Watch) Salman Khan in a still from the 2003 romantic drama, Tere Naam. In Tere Naam, Salman played a jobless rabble rouser called Radhe Mohan who might be a rowdy himself but likes doling out his own form of justice. However, the look was inspired by someone who's on the opposite end of the spectrum of Radhe – former Indian President APJ Abdul Kalam. On the first episode of The Great Indian Kapil Show, the actor shared, 'Ye jo Tere Naam ka jo look hai, woh actually inspired tha Abdul Kalam saab se aur uss dauran I think Rahul Roy ka bhi same hairstyle tha. I thought ki jo small town hero hota hai na, unke humesha lambe baal hotey hai. The yesteryear heroes all had long hair, toh waha se ye aaya tha. (My hair in Tere Naam is inspired by Abdul Kalam sir, even Rahul Roy had the same hairstyle. I thought a small town hero would have long hair like this. The yesteryear heroes all had long hair, which inspired me).' The third season of The Great Indian Kapil Show kicked off with Salman as a guest on 21 June. Recent work Tere Naam, directed by Satish Kaushik, is a remake of Bala's 1999 Vikram-starrer Sethu. Bhumika Chawla made her Hindi debut with the film. The film was a moderate success at the box office, with criticism for the way Radhe treats Bhumika's character, Nirjala, but Salman's performance is considered one of the best in his career. After the 2023 film Tiger 3, and cameos in 2024 films Singham Again and Baby John, Salman starred in AR Murugadoss' Sikandar this year. He will soon star in the Saudi Arabian-Egyptian film 7 Dogs, which also stars Sanjay Dutt. He has yet to announce his upcoming projects.
Time of India
12-06-2025
- Business
- Time of India
US tech firm Datadog sets up Bengaluru office to drive Asia-Pacific expansion: Vice president Rob Thorne
Rob Thorne NEW YORK: Bengaluru is fast becoming a cornerstone of Datadog's global operations, with the cloud monitoring and security firm significantly ramping up its presence in India. In an interview with The Times of India on the sidelines of the DASH 2025 conference in New York, Rob Thorne, vice president for Asia Pacific and Japan (APJ), said the city now houses the company's new India headquarters in Bengaluru and a rapidly growing team of close to 100 professionals. Datadog already has a strong global presence with key offices in New York, Paris, Dublin, San Francisco, Amsterdam, Singapore, Japan, Australia—and Asia‑Pacific hubs like Singapore and Japan . Excerpts : How important is the Indian market to Datadog's global and APJ operations? India plays a critical role, not just within APJ but globally. Over the past 18 months, we've seen unprecedented customer demand. We've grown our local team significantly and established a new headquarters in Bengaluru. The silicon city is now a major strategic hub for us. What kind of Indian companies are adopting Datadog's solutions? Adoption is broad-based. We're seeing uptake from startups, mid-sized firms, and large enterprises. While digital-native businesses lead in adoption, we're also working with companies in traditional sectors—banking, finance, retail, manufacturing, and services. Can you name some of the Indian customers you work with? While we can't name all due to confidentiality, one of India's top two food delivery platforms is a major client. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Pinga-Pinga e HBP? Tome isso 1x ao dia se tem mais de 40 anos Portal Saúde do Homem Clique aqui Undo They depend on Datadog to maintain uptime and performance, particularly during peak periods. Jubilant Foodeorks, which runs Domino's Pizza in India, also uses our platform to consolidate monitoring tools and accelerate issue resolution. Is Datadog planning further expansion in India? Definitely. Just two years ago, we had one seller in India. Today, we have over 40 professionals across sales and support functions. We've already invested in new office space in Bengaluru and are preparing for further expansion as demand grows. How is the company navigating India's data privacy and localisation regulations? Data residency requirements in sectors like public services and banking pose challenges. We understand this is a priority for the market and are actively exploring ways to meet local compliance standards. What role does Indian tech talent play in Datadog's strategy? Indian talent is fundamental to our growth. We're not just building sales teams in Bengaluru but also pre-sales, post-sales, and customer support. Though we haven't moved core engineering functions here yet, the talent pipeline is strong, and we're optimistic about future possibilities. Where do you see the biggest growth areas for Datadog in India? Digital-native companies are our biggest opportunity. As they grow and mature, they tend to expand their use of our observability and security tools. We aim to support them through that journey. How does India fit into Datadog's AI strategy? India is highly receptive to cutting-edge tech. Our AI-enhanced observability solutions are gaining traction here. Customers are focused on boosting efficiency and user experience, and our tools—from GPU-level monitoring to end-user analytics—fit well with India's tech-forward momentum. What's your approach to cybersecurity in the Indian market? Security is integral to our platform. Globally, over 7,500 customers use our security suite. In India, we're helping businesses integrate devops and security to improve threat response. Our unified approach covers posture management, detection, and resolution, ensuring agility and resilience.
Techday NZ
12-06-2025
- Business
- Techday NZ
Amplitude unveils AI Agents to automate digital product growth
Amplitude has launched Amplitude AI Agents, a new suite of artificial intelligence-driven assistants designed to automate a range of product development and management tasks. Amplitude's AI Agents are intended to function as a team of specialised experts, supporting organisations in achieving goals such as improved checkout conversion rates and faster feature adoption. The agents analyse user behaviour, run experiments and optimise product experiences to help teams work more efficiently and effectively. Resource challenges The company highlights that resource constraints are common among product, marketing and data teams. Gathering data, generating dashboards, running queries, and testing hypotheses are often time-consuming tasks. Such work can be hindered by limited team capacity, leaving little room for strategic planning or execution. With the introduction of Amplitude AI Agents, organisations are expected to be able to explore, test and iterate more rapidly. The agents can monitor data, detect patterns, observe user sessions, form and test hypotheses, implement changes and measure their impact—all while human teams focus on strategic goals and creative problem-solving. Teams can instruct agents on specific focus areas, such as conversion, engagement, or campaign performance, and the agents will then begin their tasks based on these guidelines. Executives' perspectives "The pressure to turn data into real outcomes is growing across Australia and New Zealand — yet many teams are still struggling to make that leap," said Mark Drasutis, Head of Value, APJ at Amplitude. "Many don't have the time, tooling and resources to use data effectively, but Amplitude's AI Agents change that. They don't just focus on writing code, they also allow you to automate product management tasks and experimentation at scale. These agents unlock the ability for teams to solve problems that previously felt out of reach and more efficiently improve the customer experience." The issue of user trust with enterprise AI agents has previously been a concern, as some solutions have made changes autonomously. Amplitude states that its customers retain control over the autonomy level of their AI Agents. Organisations can set guardrails and approve any customer-facing changes, ensuring that the AI Agents function under human oversight. Use case templates Amplitude plans to release multiple use-case-specific AI Agent templates. These include: Website Conversion Agent, which monitors performance metrics and investigates conversion drops by analysing user sessions, subsequently recommending improvements. Onboarding Agent, which identifies points where users hesitate or abandon onboarding, and then creates in-app guides tailored to assist specific user segments. Feature Adoption Agent, which analyses engagement with new product features across different user groups, offering targeted recommendations for increasing adoption rates. Monetisation Agent, which detects signs that users are ready to upgrade or purchase premium features, and suggests interventions such as in-product messages or special offers. Vinay Sharma, Head of Software Engineering at Yum! Brands, commented on the potential for these agents to streamline and accelerate product development processes. "What excites me most about Amplitude's AI Agents isn't just that they can identify conversion issues or run experiments - it's that they'll be able to work through dozens of scenarios and execute toward our goals while our team focuses on higher-level strategy," said Vinay Sharma, Head of Software Engineering at Yum! Brands. "The traditional product development process gets bottlenecked by resource constraints, but Amplitude is changing that. With Agents, it'll be much faster and easier to understand customer behaviour, identify optimisation opportunities, and measure impact." Spenser Skates, Chief Executive Officer and co-founder of Amplitude, noted that demand for AI Agents has been high. "AI Agents were our most-wanted new product at multiple customer advisory boards this year," said Spenser Skates, CEO and co-founder of Amplitude. "They give our customers an edge in building products people love, and they mark the beginning of a broader AI evolution at Amplitude." Platform integration Amplitude's AI Agents are integrated across the company's Digital Analytics Platform, leveraging data from Analytics, Session Replay, Experimentation and Guides and Survey modules. According to the company, the agents not only use organisation-specific data but also apply insights observed across thousands of teams that use Amplitude's platform. The new agents are positioned as a response to increasing demand for more automated and scalable solutions in digital product development and optimisation. Follow us on: Share on:
